Representatives of the two councils to say, Class B OTC to stay in the health care directory to meet the turning point?

At the end of April,, this news, the industry response is strongDuring the two sessions, npc representatives also submitted proposals to keep Class B OTCs in the health insurance catalogueApril 29, the State Medical Insurance Administration issued the Interim Measures for the Administration of Drug Use for Basic Medical Insurance (Draft for Comments), which includes the determination and adjustment of the scope of drug use for basic medical insurance, as well as the payment, management and supervision of the use of essential medical insurance drugsIn the draft opinion, the National Health Insurance Administration clearly does not include 10 categories of medicines such as health drugs and class B OTC drugs in the medical insurance cataloguethe draft also mentions that the health insurance directory is adjusted once a year, and that the inclusion of the health insurance catalogue further emphasizes clinical necessity, safety, effectiveness and economythe news that health insurance is not included in OTC drugs, the industry has been talking aboutOTC is short for out-of-the-counter drugs, OTC is divided into two categories of A and B, Class B OTC drugs can be purchased and used without the guidance of a physician or pharmacistThe health care adjustment is clearly not included in class B OTC, the industry believes that this will undoubtedly hit some enterprises with such products, especially such varieties of productsaccording to the relevant statistics, China's 2019 version of the National Medical Insurance Drug Catalog included in the 2705 kinds of OTC drugs 617, accounting for 23%, of which Class A OTC has 485, Class B OTC has 121, due to dosage form or specifications of different Class A OTC have 11Among them, there is no shortage ofand other popular productsGuosheng Securities believes that the adjustment of the medical insurance catalog is to propose "not included", and directly transferred out and may be transferred out of the scope of the drug is not mentioned, the original inclusion in the health insurance catalog of Class B OTC or does not constitute an impactAnd assuming that the stock of varieties is transferred out, the proportion of such drugs in listed pharmacies is small, the impact is relatively controllablesince the release of the above-mentioned opinion draft, the industry has reported that the China Association of Over-the-counter Drugs proposed amendments to the Draft for Comments, and strongly recommended that the National Health Insurance Administration remove the special restrictions on the inclusion of Class B OTC drugs in the medical insurance directoryChina Over-the-counter Drug Association believes that China's OTC accounts for only 4% of the annual expenditure of the health insurance fund, OTC health insurance policy reform should be improved from the payment channels and payment methods, medical insurance catalog should follow the clinical necessity, safe and effective, reasonable price basic conditions, it is not appropriate to "OTC" as a decision factor in the medical insurance directoryduring the two sessions of the National People's Congress, there are also representatives of the National People's Congress to make suggestions on this at the 2020 National People's Congress (CPPCC) symposium held on the morning of May 21, The National People's Congress representative, Fang Tonghua, chairman of Treasure Island Pharmaceuticals, suggested that the medical insurance catalogue retain class B OTC drugs Fang Donghua said that for a long time, Class B OTC drugs have been in the medical insurance catalog, the basic drug catalog occupies a certain proportion, patients on Class B OTC drugs high awareness, high acceptance He suggested that the State retain Class B OTC drugs, revise the draft medical insurance system recommendations, and eliminate the provisions of Article 8 that "Class B OTC Drugs" will not be included in the Drug Catalog Xiao Wei, a representative of the National People's Congress and chairman of Kangyuan Pharmaceuticals, also submitted a proposal, arguing that over-the-counter drugs should be avoided "one size fits all" to the simple approach of moving out of the health insurance list Some over-the-counter drugs that have been used for a long period of time and are identified as safe, effective and stable quality varieties should be able to enter the health insurance catalogue in accordance with statutory rules and procedures to avoid reimbursement for over-the-counter drugs For example, encouraging clinically preferred and special over-the-counter varieties, special populations and diseases commonly or necessary over-the-counter chronic disease sage, OTC brand chinese traditional medicines, etc may be considered for inclusion in the health insurance list of concern is that as early as last April, the National Health Insurance Administration officially announced the 2019 National Health Insurance Drug Catalog Adjustment Work Program has mentioned that for over-the-counter drugs (OTC), the international general non-reimbursement, this adjustment in principle is no longer added can see that Class B OTC into health insurance road has been difficult This opinion draft points out that no longer include class B OTC drugs, whether this means that the original access to the health insurance catalog of related drugs will also be cleaned up, the follow-up we will continue to pay attention to (Note: Comprehensive)